Renvelasevelamer carbonate
According to the FDA label: Sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis. Sevelamer carbonate tablet is a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis. (1 )
11,349 adverse event reports submitted to the FDA (2008–2026)
Top Reported Adverse Events
The most frequently reported events in association with Renvela in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
Constipation 2,541 reports
Difficulty passing stool, or having fewer bowel movements than usual.
Full definition in the glossary → See all drugs reporting this event →Diarrhoea 1,030 reports
Loose or watery bowel movements, often frequent. Also spelled diarrhea in American English.
Full definition in the glossary → See all drugs reporting this event →Pruritus 1,008 reports
Nausea 813 reports
The feeling of sickness in your stomach that often comes before vomiting.
Full definition in the glossary → See all drugs reporting this event →Chronic Kidney Disease 676 reports
A long-term, gradual loss of kidney function over months or years.
Full definition in the glossary →End Stage Renal Disease 671 reports
The final stage of chronic kidney disease, where the kidneys can no longer function well enough to sustain the body without dialysis or a transplant. Renal means related to the kidneys.
Full definition in the glossary →Renal Failure 663 reports
A serious decline in kidney function, where the kidneys can no longer filter waste properly.
Full definition in the glossary →Death 622 reports
A report that the person died. A death appearing in reports for a drug does not mean the drug caused it. Reports record that a death occurred while the medication was being used, which can happen for many unrelated reasons.
Full definition in the glossary →Vomiting 526 reports
Throwing up the contents of the stomach.
Full definition in the glossary → See all drugs reporting this event →Acute Kidney Injury 508 reports
A sudden drop in how well the kidneys are working. It is often temporary and can have many causes.
Full definition in the glossary →Abdominal Pain 305 reports
Pain in the belly or stomach area.
Full definition in the glossary → See all drugs reporting this event →- Nephrogenic Anaemia 297 reports
Dyspnoea 291 reports
Shortness of breath or difficulty breathing. Also spelled dyspnea in American English.
Full definition in the glossary → See all drugs reporting this event →Fatigue 262 reports
Extreme tiredness or lack of energy that does not improve with rest.
Full definition in the glossary → See all drugs reporting this event →Flatulence 251 reports
Excess gas in the digestive system, commonly called passing gas.
Full definition in the glossary →
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Male | 3,700 |
| Female | 3,388 |
| Unknown | 608 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 135 |
| 18-34 | 275 |
| 35-49 | 710 |
| 50-64 | 1,692 |
| 65-74 | 1,242 |
| 75+ | 881 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Renvela. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Non-Serious | 5,808 |
| Other Serious | 3,044 |
| Hospitalization | 2,984 |
| Death | 1,212 |
| Life-Threatening | 229 |
| Disability | 157 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Renvela. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2008 | 4 |
| 2009 | 54 |
| 2010 | 74 |
| 2011 | 164 |
| 2012 | 239 |
| 2013 | 1,071 |
| 2014 | 3,605 |
| 2015 | 890 |
| 2016 | 678 |
| 2017 | 875 |
| 2018 | 824 |
| 2019 | 790 |
| 2020 | 487 |
| 2021 | 368 |
| 2022 | 277 |
| 2023 | 262 |
| 2024 | 273 |
| 2025 | 353 |
| 2026 (partial) | 61 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Medications commonly reported with Renvela
In FDA adverse event reports that mention Renvela, these medications appeared most often in the same report.
- Furosemide (1,299 reports)
- Omeprazole (1,258 reports)
- Aspirin (1,204 reports)
- Carvedilol (1,160 reports)
- Cinacalcet (1,134 reports)
This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026